Trials soon ready
Clinical trials expected to report results within the next 3 months, ranked by how much the coming result could matter. Each trial shows its estimated finish date, explained in plain language.
This page shows companies working on cures and vaccines first, on purpose. We believe investor interest in cures leads to more cure trials. Why we do this.
Showing the top 50 of 11775 trials in this window.
Results due in the coming weeks
These trials are in their final phase, the companies running them are on the stock market, and results are due within weeks. A final-phase result is usually the last big test before a treatment can be approved, and it can move the company's value in either direction. We list them up top so you see the nearest dates first.
-
Gene therapy slows vision loss in stargardt disease trial Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
Sharper eye for prostate cancer: new imaging agent aims to spot hidden spread Results expected Sep 2026 (estimated) 🚀 Make-or-breakClarity Pharmaceuticals Ltd ASX: CU6
-
New hepatitis c pill aims to cut treatment time in half Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
New hope for chronic hives: barzolvolimab in Late-Stage trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
-
Rabies vaccine batch check: will it pass the test? Results expected Sep 2026 (estimated) 🚀 Make-or-breakSinovac Biotech Co., Ltd. NASDAQ: SVA
The weekly investor briefing
One email every Sunday: which trial results are due in the coming weeks, what read out in the past week, and the small companies with a make-or-break result ahead. Free, and every issue has a one-click unsubscribe.
We'll send one confirmation email first — you're not subscribed until you click it.
-
One-Time gene therapy aims to restore muscle in boys with duchenne
Disease control OngoingRGX-202 is a gene therapy designed to deliver a transgene for a novel microdystrophin that includes functional elements of naturally-occurring dystrophin including the C-Terminal (CT) domain. This is a multicenter, open-label dose evaluation clinical study to assess the safety, …
Results expected Sep 2026 (estimated)
Phase 2/3 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
Result impact 🚀 Make-or-breakVery highSmall-cap Phase 3, decisive Readout dueA result this decisive could redraw a company this size.
RegenxBio Inc. · RGNX NASDAQ Trade on eToro (ad)Why investors are watching
RegenxBio is testing RGX-202, a one-time gene therapy for Duchenne muscular dystrophy, in a 65-patient study that combines phase 2 and phase 3. For a small company, this trial is the main driver of its value, because a positive result could support regulatory approval and a negative result would leave it without a clear path forward.
If it works: If RGX-202 shows it is safe and helps boys with Duchenne, RegenxBio could move closer to bringing the therapy to market. That outcome would validate the company's core science and give it a product to sell.
If it fails: Gene therapy trials often fail on safety or effectiveness, and this one is still in early testing. A failure or delay could leave RegenxBio with no approved product and little reason for investors to stay.
AI-written from the trial record. Speculative, and not investment advice.
-
Can a shorter radiation course spare the rectum in rectal cancer?
Cure OngoingThe hereby proposed ACO/ARO/AIO-18.1 randomized trial aims to directly compare the newly established TNT concepts applying either short-course RT according to RAPIDO, or CRT according to CAO/ARO/AIO-04/-12, both followed by consolidation chemotherapy, and surgery or a watch\&wait…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Prof. Dr. med. Claus Rödel • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
-
One shot, six months of malaria shield? a new trial tests a powerful antibody in children
Prevention OngoingBackground and rationale: Hospitalised children with severe anaemia remain at high risk of dying or requiring hospital readmission for at least 6 months after discharge. In highly malaria-endemic settings, malaria is a major contributor to these post-discharge readmissions and de…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Liverpool School of Tropical Medicine • Aim: Prevention
Last updated Aug 07, 2026 00:00 UTC
-
New hope for kids with blood cancer: tailored treatments aim to boost cure rates and cut side effects
Disease control OngoingThe overarching objective of this study is to use novel precision medicine strategies based on inherited and acquired leukemia-specific genomic features and targeted treatment approaches to improve the cure rate and quality of life of children with acute lymphoblastic leukemia (A…
Results expected Sep 2026 (estimated)
Phase 2/3 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a Virus-Like particle vaccine outsmart polio?
Vaccine OngoingThis is a phase I/II randomized, double-blind, and positive-controlled study. Participants in the phase I toddler group will receive 1 dose of either high dose VLP-Polio (Dose H) or control vaccine in a ratio of 3:1. The phase I infant cohort will have 4 arms randomly assigned to…
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 08, 2026 00:03 UTC
Result impactVery highSmall-cap Phase 2 Readout in ~1 wkA small company. This result carries real weight for it.
CanSino Biologics Inc. · 6185 HKEXWhy investors are watching
CanSino Biologics is testing a new polio vaccine that uses virus-like particles instead of the traditional live or inactivated virus. This trial checks the vaccine's safety and immune response in infants and toddlers, and a positive result could give the small company a new product in a global market with steady demand. Because CanSino is small, this single trial's outcome can meaningfully affect its value and reputation.
If it works: A successful readout could position CanSino as a leader in next-generation polio vaccines, potentially opening partnerships or licensing deals with larger organizations. It may also validate the company's VLP platform for other vaccines, broadening its pipeline.
If it fails: The trial could fail to show adequate immune response or safety, which would set back the program and hurt investor confidence. Trials at this stage often fail, and any delay in enrollment or dosing could also weigh on the company's prospects.
AI-written from the trial record. Speculative, and not investment advice.
-
Could a stem cell transplant cure immune diseases?
Cure Recruiting nowBackground: During a transplant, blood stem cells from one person are given to someone else. The cells grow into the different cells that make up the immune system. This can cure people with certain immunodeficiencies. But transplant has many risks and complications. Objective:…
Results expected Oct 2026 (estimated)
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Cure
Last updated Aug 21, 2026 00:00 UTC
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
Cure OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: Arcellx, Inc. • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Result impactModerateLarge company Follow-on study Readout in ~1 wkA follow-on study — an extension, safety or dosing run, not the deciding result.
-
Can specially trained immune cells flush out hidden HIV?
Cure OngoingThis is a multi-site phase 1 study of the safety, immunologic and virologic responses of ex vivo expanded donor-derived (DD) HIV-1 multi-antigen specific T-cell (HST) with non-escaped epitope targeting (NEET) therapy as a therapeutic strategy in HIV-infected individuals following…
Results expected Nov 2026 (estimated)
Phase 1 • Sponsor: Catherine Bollard • Aim: Cure
Last updated Aug 16, 2026 00:00 UTC
-
Could one drug replace the standard triple therapy for rectal cancer?
Disease control OngoingThe purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical respon…
Results expected Nov 2026 (estimated)
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 2 Readout in ~6 wkA large company. One readout moves the needle only so far.
-
New hope for advanced breast cancer: targeted drug combo tested in major trial
Disease control OngoingThe study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
May already have reported ↗ AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap May already have reported Readout in ~2 moThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-03-16 → -
One-Time gene shot aims to stop bleeding in hemophilia a
Disease control Recruiting nowThis study is a single-arm, open-label, multicenter study evaluating the efficacy and safety of GS1191-0445 injection as a single dose in Chinese subjects with hemophilia A. GS1191-0445 is an AAV8-based gene therapy vector designed to express B-domain deleted human factor VIII (…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: Gritgen Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for kids with leukemia: smarter chemo dosing could boost cures
Cure OngoingAcute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous ly…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: Dana-Farber Cancer Institute • Aim: Cure
Last updated Jul 18, 2026 00:00 UTC
-
Can a single radiation dose cure large liver tumors?
Cure Recruiting nowThe RESCUE trial is a prospective, single-arm clinical study to evaluate the efficacy and safety of ablative radioembolization using Yttrium-90. This treatment is being investigated as a potential curative approach, as well as a bridging or downstaging strategy for surgery, in pa…
Results expected Nov 2026 (estimated)
Phase 2 • Sponsor: Seoul National University Hospital • Aim: Cure
Last updated Aug 22, 2026 00:00 UTC
-
One blood draw, many cancers: AI model aims to spot tumors early
Diagnosis Recruiting nowThis study is a multi-center, case-control study aiming at developing and blinded testing machine learning-based multiple cancers early detection model by prospectively collecting blood samples from newly diagnosed cancer patients and individuals without confirmed cancer diagnosi…
Results expected Oct 2026 (estimated)
Sponsor: Shanghai Weihe Medical Laboratory Co., Ltd. • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Engineered immune cells target CD5 in Hard-to-Treat T-Cell lymphomas
Cure Recruiting nowThis is a multi-center, open-label, non-randomized, single-arm clinical trial. Refractory/relapse T-NHL patients are treated with autologous and allogeneic CD5 CAR T-cell therapy. The primary objective is to prospectively evaluate the safety of CD5 CAR T cell bridging to HSCT in …
Results expected Nov 2026 (estimated)
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Cure
Last updated Sep 13, 2026 00:00 UTC
-
Can a Three-Drug cocktail before surgery stop small cell lung cancer from returning?
Cure Recruiting nowThis is a single-arm, prospective, exploratory phase II clinical study. The study enrolled newly diagnosed stage T1-3N0-1M0 resectable limited-stage small cell lung cancer. Adebrelimab combined with chemotherapy for 4 cycles and apatinib mesylate for 3 cycles. Surgery was perform…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: Jin Ying • Aim: Cure
Last updated Sep 13, 2026 00:00 UTC
-
Engineered immune cells target CD70 in kidney cancer
Cure OngoingThis is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.
Results expected Dec 2026 (estimated)
Phase 1/2 • Sponsor: Adicet Therapeutics • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
Result impactVery highMicro-cap Phase 2 Readout in ~2 moA small company. This result carries real weight for it.
Adicet Bio · ACET NASDAQ Trade on eToro (ad)Why investors are watching
Adicet Bio runs this Phase 1/2 trial of ADI-270, an engineered gamma-delta CAR Vδ1 T cell therapy that targets CD70, in adults with relapsed or refractory clear cell renal cell carcinoma. The study tests dose escalation and dose expansion across 60 planned participants. For a micro-cap company, this readout carries the whole story: it is the main evidence that the platform works in patients.
If it works: A positive result could support further development of ADI-270 and draw partner or financing interest. It may also validate the company's engineered gamma-delta T cell approach beyond this one cancer.
If it fails: Early-phase trials often fail on safety, tolerability, or signs of benefit. A failure or delay could leave the company with limited clinical momentum and few other late-stage assets.
AI-written from the trial record. Speculative, and not investment advice.
-
Can adding radiation boost immunotherapy against spread head and neck cancer?
Disease control Recruiting nowStudy to evaluate the efficacy of treatment by radiotherapy and pembrolizumab in newly diagnosed metastatic head \& neck cancers
Results expected Oct 2026 (estimated)
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could brain implants tame severe mental illness?
Disease control Recruiting nowThis is a multi-center, single arm, prospective, open-label, extendable study for the efficacy and safety of combo-stim deep brain stimulation for treatment-refractory mental disorders (obsessive-compulsive disorder, schizophrenia, bipolar with depression, anorexia nervosa, gambl…
Results expected Nov 2026 (estimated)
Sponsor: Shanghai Mental Health Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Womb transplants could let infertile women give birth
Disease control OngoingThis study aims to investigate the treatment of absolute uterine infertility (AUI) due to congenital or surgical absence of a uterus or presence of a nonfunctioning uterus. The investigators will follow a model based on a Swedish study to enroll 20 women with functioning ovaries …
Results expected Nov 2026 (estimated)
Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
Cure Recruiting nowEnrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFO…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: Weill Medical College of Cornell University • Aim: Cure
Last updated Jul 31, 2026 00:00 UTC
-
A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease
Cure Recruiting nowThis is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical or MUD allogeneic stem cell transplantation with CD…
Results expected Dec 2026 (estimated)
Phase 2 • Sponsor: New York Medical College • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
New TB vaccine aims to prevent active lung disease in adults
Vaccine OngoingThis study is a multicenter, double-blind, randomized, placebo-controlled Phase III trial designed to evaluate the efficacy and safety of the GamTBvac recombinant subunit tuberculosis vaccine for the prevention of active non-HIV-associated pulmonary tuberculosis. The study is di…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation • Aim: Vaccine
Last updated Jul 08, 2026 00:00 UTC
-
Can a catheter valve replace Open-Heart surgery for a leaky heart valve?
Disease control OngoingThe TricValve® Transcatheter Bicaval Valve System is a bicaval transcatheter tricuspid valve replacement system, which includes the TricValve® Transcatheter Bicaval Valve for superior vena cava (SVC) and the TricValve® Transcatheter Bicaval Valve for inferior vena cava (IVC). The…
Results expected Sep 2026 (estimated)
Sponsor: P+F Products + Features USA Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a daily pill target hard-to-treat cancers with EGFR or HER2 mutations?
Disease control Recruiting nowThe purpose of this study is to establish the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD), safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of ORIC-114 as a Single Agent or in Combination with Chemotherapy when administered to p…
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: ORIC Pharmaceuticals • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
Result impactVery highSmall-cap Phase 2 Readout dueA small company. This result carries real weight for it.
ORIC Pharmaceuticals · ORIC NASDAQ Trade on eToro (ad)Why investors are watching
ORIC Pharmaceuticals is testing ORIC-114, its lead drug candidate, in patients with advanced solid tumors that have EGFR or HER2 alterations. The trial aims to find the right dose and measure safety and anti-tumor activity, both alone and with chemotherapy. For a small company, this readout is a major test of whether its drug works and can support further development.
If it works: A positive result could show that ORIC-114 controls disease in a defined patient group, which may strengthen the company's position and support advancing the drug to later-stage trials. It could also validate the drug's potential as a treatment option for these tumor types.
If it fails: A failure or delay could set back the company's pipeline and hurt its prospects, since ORIC-114 appears to be a central asset. Trials often fail to meet their goals, so a negative outcome is a real possibility.
AI-written from the trial record. Speculative, and not investment advice.
-
New combo therapy shows promise for tough-to-treat lymphoma
Disease control OngoingThis is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
Incyte · INCY NASDAQ Trade on eToro (ad)Result impactHighLarge company Phase 3, decisive Readout dueA large company. One readout moves the needle only so far.
-
Meningitis b vaccine tested as gonorrhea shield in men
Prevention OngoingObjectives: Efficacy of a meningococcal vaccine against Neisseria gonorrhoea (NG) infection among men who have sex with men (MSM). Design: Parallel randomised double-blind placebo-controlled trial. Setting: A teaching hospital in Hong Kong. Participants: 150 adult MSM at risk …
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Chinese University of Hong Kong • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
Can a Dual-Action antibody outsmart resistant tumors?
Disease control Recruiting nowGIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanc…
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can precision dosing make a lifesaving sickle cell drug safer for african children?
Disease control Recruiting nowSickle cell anemia (SCA) is among the world's most common and devastating blood disorders, affecting more than 300,000 newborns per year. Most infants with SCA are born in the low-resource settings of sub- Saharan Africa, where an estimated 50-90% will die before 5 years of age d…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Brown University • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Triple threat: new combo aims to outsmart advanced liver cancer
Disease control Recruiting nowTHis study aims to evaluate the efficacy of SHR-8068 combined with Adebrelimab and Bevacizumab compared with Sintilimab or Atezolizumab combined with Bevacizumab for the first-line treatment of advanced HCC.
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can a daily pill ease a stiff heart condition?
Disease control OngoingThe study is being conducted to evaluate the efficacy and safety of HRS-1893 for obstructive hypertrophic cardiomyopathy.
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Shandong Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
First human trial of Gene-Edited lung cells for rare breathing disorder
Disease control Recruiting nowThe major goal of this study is to evaluate a new type of cell transplantation therapy for individuals with hereditary PAP, study a new treatment that may be useful for treatment of other diseases, and research mechanisms that drive the development and function of lung macrophage…
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Experimental vaccine combo takes on childhood brain cancer
Disease control Recruiting nowThis is a phase I, open label, plus expansion clinical trial evaluating the safety and tolerability of rHSC-DIPGVax in combination with BALSTILIMAB and ZALIFRELIMAB. rHSC-DIPGVax is an off-the-shelf neo-antigen heat shock protein containing 16 peptides reflecting neo-epitopes fou…
Results expected Sep 2026 (estimated)
Phase 1 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Experimental therapy offers hope for kids with Tough-to-Treat leukemia
Disease control Recruiting nowA Phase 1 clinical trial to evaluate the safety and early efficacy of Chimeric Antigen Receptor T-cell (CAR T-cell) with IL-7Rα signaling targeting CD19 in children with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (ALL) after complete standard treatments.
Results expected Sep 2026 (estimated)
Phase 1 • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Your genes could guide safer drug doses
Prevention OngoingIn PT@LUMC 2000 patients will be randomized between a PGx-guided dosing group and a standard of care group. The patients will be followed for one year in which they will be asked to report adverse drug reactions at one, three, six and twelve months.
Results expected Sep 2026 (estimated)
Sponsor: Leiden University Medical Center • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
New pill zongertinib takes on HER2 lung cancer in major trial
Disease control OngoingThis study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer.…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
One-Time gene therapy could free hemophilia patients from frequent infusions
Disease control OngoingIn this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a heal…
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
Bayer AG · BAYN XETRAResult impactModerateMega-cap Phase 2 Readout dueA large company. One readout moves the needle only so far.
-
Could this Stem-Cell infusion end insulin shots for diabetics with kidney transplants?
Disease control Recruiting nowThis study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
Vertex Pharmaceuticals Incorporated · VRTX NASDAQ Trade on eToro (ad)Result impactHighLarge company Phase 3, decisive Readout dueA large company. One readout moves the needle only so far.
-
New chikungunya vaccine trial aims to protect millions
Vaccine Recruiting nowA Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age
Results expected Sep 2026 (estimated)
Phase 2/3 • Sponsor: Bharat Biotech International Limited • Aim: Vaccine
Last updated Jun 27, 2026 12:24 UTC
-
New hope for High-Risk leukemia: stem cell transplant trial launches
Disease control Recruiting nowFor newly diagnosed high-relapse-risk core-binding-factor acute myeloid leukemia participants, the investigators aim to perform allogeneic hematopoietic stem cell transplantation after participants finished one cycle of induction and two cycles of consolidation. To access whether…
Results expected Sep 2026 (estimated)
Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Could a drug cocktail slash deaths from TB of the brain?
Disease control Recruiting nowINTENSE-TBM is randomized controlled, phase III, multicenter, 2 x 2 factorial plan superiority trial assessing the efficacity of two interventions to reduce mortality from tuberculous meningitis (TBM) in adolescents and adults with or without HIV-infection in sub-Saharan Africa: …
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: ANRS, Emerging Infectious Diseases • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Gene therapy slows vision loss in stargardt disease trial
Disease control OngoingPhase 2/3 Pivotal Confirmatory Clinical Trial is a randomized, outcome assessor-masked, multicenter study, that will enroll fifty-one (51) subjects. Subjects will be enrolled in a 2:1 ratio to either the treatment group (n=34 subjects) or to an untreated control group (n=17 subje…
Results expected Sep 2026 (estimated)
Phase 2/3 • Sponsor: Ocugen • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
May already have reported ↗Result impact 🚀 Make-or-breakVery highMicro-cap May already have reported Readout in ~1 wkThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-09-08 →Ocugen · OCGN NASDAQ Trade on eToro (ad)Why investors are watching
Ocugen is a micro-cap company whose value depends heavily on its eye disease pipeline. This trial tests OCU410ST, a gene therapy for Stargardt disease, a rare inherited condition that causes vision loss. Phase 1 data showed slower lesion growth and stable vision in treated eyes, and this larger Phase 2/3 study will confirm whether those benefits hold in a controlled setting.
If it works: A positive Phase 2/3 result could establish OCU410ST as a viable treatment for a disease with no approved therapy. That would give Ocugen a clear path toward regulatory approval and a commercial product, which would be a major milestone for a company of this size.
If it fails: Phase 2/3 trials often fail even after promising early data. If OCU410ST does not show a clear benefit over the untreated control group, or if safety problems appear, the company would face a significant setback with no approved product to fall back on.
AI-written from the trial record. Speculative, and not investment advice.
-
Engineered immune cells take on tough T-Cell cancers in new trial
Disease control Not yet recruitingTo Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.
Results expected Sep 2026 (estimated)
Phase 2 • Sponsor: Hebei Senlang Biotechnology Inc., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug cocktail aims to stall lung cancer progression
Disease control OngoingThis is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unr…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~1 wkA large company. One readout moves the needle only so far.
-
New hope for EGFR lung cancer: Dato-DXd combo tested in phase 3 trial
Disease control Recruiting nowThis study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~1 wkA large company. One readout moves the needle only so far.
-
New hope for advanced stomach cancer: experimental combo targets HER2-positive tumors
Disease control OngoingThis study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach …
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
Jazz Pharmaceuticals · JAZZ NASDAQ Trade on eToro (ad)Result impactHighMid-cap Phase 3, decisive Readout in ~1 wkA mid-sized company with other programmes alongside this one.
-
New drug cocktail targets Hard-to-Treat lung cancer mutation
Disease control OngoingStudy CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Results expected Sep 2026 (estimated)
Phase 2 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
Bristol-Myers Squibb Company · BMY NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 2 Readout in ~1 wkA large company. One readout moves the needle only so far.
-
Double attack on tough myeloma: stem cell transplant plus CAR-T cells
Disease control Recruiting nowThis is a phase I/II, single-arm, open-lable study of autologous stem cell transplantation in combination with C-CAR088, an autologous BCMA CAR-T cell product, for patients with ulta high-risk multiple myeloma, defined as failed or unsatisfied responses to front line VRD-based tr…
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New gene therapy targets rare, aggressive ALS
Disease control OngoingThis is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: UniQure Biopharma B.V. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
Result impactHighSmall-cap Phase 2 Readout in ~1 wkA small company. This result carries real weight for it.
uniQure · QURE NASDAQ Trade on eToro (ad)Why investors are watching
uniQure is testing AMT-162, a gene therapy given directly into the spinal fluid, in 20 adults with a rare, inherited form of ALS caused by SOD1 mutations. This early-stage trial measures safety and whether the therapy slows the disease. For a small company like uniQure, this readout matters because it could validate their gene therapy platform in a new disease area.
If it works: If the trial shows AMT-162 is safe and hints at slowing ALS progression, uniQure could advance the drug to later-stage testing. That would strengthen its pipeline and attract more attention from partners or investors.
If it fails: Gene therapies for the nervous system carry high risk, and early trials often fail to show clear benefit. A safety problem or lack of effect could set the program back and hurt uniQure's prospects, since the company's value depends heavily on its pipeline succeeding.
AI-written from the trial record. Speculative, and not investment advice.
-
Engineered immune cells take aim at Mesothelioma—Can they deliver?
Cure OngoingThis study will test the safety of MSLN-targeted CAR-T cells at different doses to find the safest dose to give to people with MPM. The researchers want to see what effects, if any, the study treatment has on people with this type of cancer. This study is the first time that an M…
Results expected Sep 2026 (estimated)
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
Why cures and vaccines come first here
We built this site so people can find trials that might cure them. These investor pages work toward the same goal from the money side: they show companies working on cures and vaccines first, and we promote those companies on purpose. We believe investor interest in cures and vaccines means more money for the companies chasing them, and more cure and vaccine trials as a result.
Nothing is hidden by this. Every trial soon ready, whatever its aim, is on the full list . Rankings are computed from the public trial record and the company's size. No company can pay to be listed or ranked higher.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. We think this page is more useful when you can go straight to somewhere that sells the stock, so the "Listed companies" view shows only companies our broker partner carries; switch to all sponsors for the unfiltered list. Ranking is never for sale: no company can pay to appear here or to place higher.